Skip to main content
Top
Published in: Acta Diabetologica 3/2013

01-06-2013 | Original Article

Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease

Authors: Federica Vinciguerra, Roberto Baratta, Maria Grazia Farina, Patrizia Tita, Giuseppa Padova, Riccardo Vigneri, Lucia Frittitta

Published in: Acta Diabetologica | Issue 3/2013

Login to get access

Abstract

The prevalence of very severe obesity has increased progressively and faster than other classes of obesity over the last years. It is unclear whether the prevalence of obesity-related complications and health risks increases progressively or reaches a plateau above a certain degree of obesity. The aim of our study was to investigate whether the severity of obesity was correlated with the prevalence of type 2 diabetes mellitus (T2DM), impaired fasting glucose, impaired glucose tolerance (IGT), metabolic syndrome (MS), and cardiovascular diseases (CVDs) in a large cohort of patients with different degrees of obesity. A cross-sectional study was conducted in 938 obese patients without a previous diagnosis of diabetes. Patients were assigned to different categories of obesity: mild-moderate obesity (BMI 30–39.9 kg/m2), morbid obesity (BMI 40–49.9 kg/m2), and super-obesity (SO, BMI ≥50 kg/m2). The prevalence of IGF, IGT, screen-detected T2DM, MS, and CVD was higher in SO patients than in the other groups. Interestingly, the association between SO and either MS or CVD was independent of glucose tolerance status, indicating that factors other than glucose metabolism also favor cardio-metabolic complications in obese patients. In patients without screen-detected T2DM (n = 807), insulin sensitivity and secretion OGTT-derived indexes indicated that SO patients had the worst glucose homeostasis relative to the other categories of obesity, which was indicated by the most reduced disposition index in these patients, a predictor of future T2DM. In conclusion, SO patients have an extremely high prevalence of glucose metabolism deterioration, and cardio-metabolic complications are more prevalent in these patients compared to less obese patients.
Literature
1.
go back to reference Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497PubMedCrossRef Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497PubMedCrossRef
2.
go back to reference Micciolo R, Di Francesco V, Fantin F, Canal L, Harris TB et al (2010) Prevalence of overweight and obesity in Italy (2001–2008): is there a rising obesity epidemic? Ann Epidemiol 20:258–264PubMedCrossRef Micciolo R, Di Francesco V, Fantin F, Canal L, Harris TB et al (2010) Prevalence of overweight and obesity in Italy (2001–2008): is there a rising obesity epidemic? Ann Epidemiol 20:258–264PubMedCrossRef
3.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 2486–2497. http://www.ncbi.nlm.nih.gov/pubmed/11368702 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 2486–2497. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11368702
4.
go back to reference Oda E (2012) Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49:89–95PubMedCrossRef Oda E (2012) Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49:89–95PubMedCrossRef
5.
go back to reference Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES et al (2010) Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 33:562–568PubMedCrossRef Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES et al (2010) Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 33:562–568PubMedCrossRef
6.
go back to reference Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE et al (2004) Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 27:2806–2812PubMedCrossRef Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE et al (2004) Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 27:2806–2812PubMedCrossRef
7.
go back to reference Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef
8.
9.
go back to reference Dixon JB, O’Brien P (2001) A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2). Int J Obes Relat Metab Disord 25:793–797PubMedCrossRef Dixon JB, O’Brien P (2001) A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2). Int J Obes Relat Metab Disord 25:793–797PubMedCrossRef
10.
go back to reference Wolf AM, Buffington C, Beisiegel U (2006) Comparison of metabolic risk factors between severely and very severely obese patients. Obesity (Silver Spring) 14:2177–2183CrossRef Wolf AM, Buffington C, Beisiegel U (2006) Comparison of metabolic risk factors between severely and very severely obese patients. Obesity (Silver Spring) 14:2177–2183CrossRef
11.
go back to reference Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS (2008) Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the national health and nutrition examination survey, 1999 to 2004. J Am Coll Surg 207:928–934PubMedCrossRef Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS (2008) Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the national health and nutrition examination survey, 1999 to 2004. J Am Coll Surg 207:928–934PubMedCrossRef
12.
go back to reference Baratta R, Amato S, Degano C, Farina MG, Patane G et al (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665–2671PubMedCrossRef Baratta R, Amato S, Degano C, Farina MG, Patane G et al (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665–2671PubMedCrossRef
14.
go back to reference Baratta R, Di Paola R, Spampinato D, Fini G, Marucci A et al (2003) Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARgamma2 (P12A) polymorphisms. J Mol Med (Berl) 81:718–723CrossRef Baratta R, Di Paola R, Spampinato D, Fini G, Marucci A et al (2003) Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARgamma2 (P12A) polymorphisms. J Mol Med (Berl) 81:718–723CrossRef
15.
go back to reference Baratta R, Rossetti P, Prudente S, Barbetti F, Sudano D et al (2008) Role of the ENPP1 K121Q polymorphism in glucose homeostasis. Diabetes 57:3360–3364PubMedCrossRef Baratta R, Rossetti P, Prudente S, Barbetti F, Sudano D et al (2008) Role of the ENPP1 K121Q polymorphism in glucose homeostasis. Diabetes 57:3360–3364PubMedCrossRef
16.
go back to reference Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544–1548PubMedCrossRef Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544–1548PubMedCrossRef
17.
go back to reference Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D et al (2006) Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 27:96–106PubMedCrossRef Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D et al (2006) Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 27:96–106PubMedCrossRef
18.
go back to reference O’Connell J, Kieran P, Gorman K, Ahern T, Cawood TJ et al (2010) BMI > or = 50 kg/m2 is associated with a younger age of onset of overweight and a high prevalence of adverse metabolic profiles. Public Health Nutr 13:1090–1098PubMedCrossRef O’Connell J, Kieran P, Gorman K, Ahern T, Cawood TJ et al (2010) BMI > or = 50 kg/m2 is associated with a younger age of onset of overweight and a high prevalence of adverse metabolic profiles. Public Health Nutr 13:1090–1098PubMedCrossRef
19.
go back to reference Ferraro KF, Thorpe RJ Jr, Wilkinson JA (2003) The life course of severe obesity: does childhood overweight matter? J Gerontol B Psychol Sci Soc Sci 58:S110–S119PubMedCrossRef Ferraro KF, Thorpe RJ Jr, Wilkinson JA (2003) The life course of severe obesity: does childhood overweight matter? J Gerontol B Psychol Sci Soc Sci 58:S110–S119PubMedCrossRef
21.
go back to reference Muntoni S, Atzori L, Mereu R, Manca A, Satta G et al (2009) Prevalence of diagnosed and undiagnosed diabetes mellitus and impaired fasting glucose in Sardinia. Acta Diabetol 46:227–231PubMedCrossRef Muntoni S, Atzori L, Mereu R, Manca A, Satta G et al (2009) Prevalence of diagnosed and undiagnosed diabetes mellitus and impaired fasting glucose in Sardinia. Acta Diabetol 46:227–231PubMedCrossRef
22.
go back to reference Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J et al (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096PubMedCrossRef Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J et al (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096PubMedCrossRef
23.
go back to reference Hanson RL, Pratley RE, Bogardus C, Narayan KM, Roumain JM et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198PubMedCrossRef Hanson RL, Pratley RE, Bogardus C, Narayan KM, Roumain JM et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198PubMedCrossRef
24.
go back to reference Goodarzi MO, Cui J, Chen YD, Hsueh WA, Guo X et al (2011) Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance. Am J Physiol Endocrinol Metab 301:E402–E408PubMedCrossRef Goodarzi MO, Cui J, Chen YD, Hsueh WA, Guo X et al (2011) Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance. Am J Physiol Endocrinol Metab 301:E402–E408PubMedCrossRef
26.
go back to reference Drapeau V, Lemieux I, Richard D, Bergeron J, Tremblay A et al (2006) Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg 16:501–509PubMedCrossRef Drapeau V, Lemieux I, Richard D, Bergeron J, Tremblay A et al (2006) Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg 16:501–509PubMedCrossRef
Metadata
Title
Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease
Authors
Federica Vinciguerra
Roberto Baratta
Maria Grazia Farina
Patrizia Tita
Giuseppa Padova
Riccardo Vigneri
Lucia Frittitta
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0460-3

Other articles of this Issue 3/2013

Acta Diabetologica 3/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.